News-Medical.Net2h
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Alternative version of Ozempic, Wegovy may not be available much longer
Affordable and alternative versions of popular weigh loss drugs, like Ozempic and Wegovy, may no longer be available.
SF Weekly14h
What to Expect When You Take Weight Loss Medication
If you’re thinking about trying weight loss medication, you probably have a lot of questions about how it works, and how fast ...
Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Fierce Pharma17h
FDA reviews Novo Nordisk's bid to expand Rybelsus as oral GLP-1 cuts heart disease risks
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Clinical trial shows oral semaglutide vastly reduces heart attacks, strokes in people with type 2 diabetes
Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
1NVO : Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...